Can-Fite BioPharma

Can-Fite completes commercial biomarker test to predict patients’ drug response

Thursday, March 19, 2015

Can-Fite BioPharma, a Israel-based biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, has completed the development of a commercial predictive biomarker blood test kit for the A3 adenosine receptor (A3AR). The biomarker test can be used at any molecular biology lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results indicate if the patient would benefit from treatment with Can-Fite’s drugs, which currently are in clinical trials for rheumatoid arthritis, psoriasis, and liver cancer.

[Read More]